Evidence-based pricing is an approach to pharma pricing, championed by Inpharmation that involves setting prices based on:
- Facts rather than opinions.
- Validated techniques rather than untested approaches or guesses.
- Simple and transparent techniques rather than unintelligible black boxes.
Inpharmation provides unique, proprietary, pharma-specific research platforms shaped by the demands of the world’s leading pharmaceutical companies over many years, rather than generic cross-industry tools.
The vast majority of top-20 global pharmaceutical companies are already using Inpharmation’s pricing solutions because of the huge benefits they bring. Inpharmation’s pricing and market access reports, models and simulators bring industry best-practice pricing techniques to answer your research questions, which is essential to sell pricing recommendations to top decision makers.
Inpharmation’s “manifesto” for evidence-based pricing and market access is contained in the book Value Pricing for Market Access: Evidence-Based Pricing for Pharmaceuticals by Inpharmation’s Managing Director, Gary Johnson. A number of the world’s leading pharma companies batch order this book to help instil an evidence-based approach to pricing and market access in their organizations.
"Europe's most respected pharma forecasting & pricing specialist consultancy."
Centre for Executive Leadership
What can evidence-based approaches to pricing for market access do for you?
Inpharmation has decades of experience developing approaches and methodologies to pricing pharmaceuticals for market access. If you’ve ever been frustrated by not having the right, relevant information needed when making pricing decisions, then you’ll understand why we developed a range of pricing techniques to determine the value of our product to the various payers.
When you start a project with Inpharmation you get access to our decades of experience in delivering pricing solutions based upon models and methodologies that have been extensively validated for use in the pharmaceutical industry. We have approaches for which ever stage of your pharmaceutical product’s lifecycle you are at. Behavior-based pricing and econometric pricing models for early stage assets. Payer Summit, Payer conjoint and probabilistic van Westendorp for products coming to market.
We also have international reference pricing simulators, launch sequence optimization and price-demand elasticity models for developing revenue maximization strategies for products near or past launch. Running Europe’s leading pharmaceutical pricing for market access executive training courses; Inpharmation places great importance on transferring knowledge and skills to you, on every project you work with us on.
The evidence behind Inpharmation’s fact-based approach to pricing is meticulously documented in the book Value Pricing for Market Access: Evidence-Based Pricing for Pharmaceuticals by Inpharmation’s Managing Director, Gary Johnson.